Fraunhofer Institute for Cell Therapy and Immunology IZICenter of Excellence to engineer advanced cell therapies
Kytopen, T-CURX, and the Fraunhofer Institute for Cell Therapy and Immunology IZI establish a Center of Excellence to develop advanced, non-viral cell therapies. The Center of Excellence will serve as a hub for innovation in non-viral cell therapy development, focusing on scalable, efficient, and clinically robust manufacturing processes.
By combining complementary expertise across technology development, translational research, and GMP manufacturing, the partners aim to accelerate the next generation of engineered cell therapies from bench to bedside. The process development through manufacturing scale-up will be led by teams at Fraunhofer IZI in Würzburg und Leipzig.
“This collaboration represents a next-generation approach to establishing advanced non-viral cell therapy processes at Fraunhofer IZI,” said Prof. Dr. Michael Hudecek, Head of the Cellular Immunotherapy Branch at Fraunhofer IZI. “Our mission is to simplify and standardize the infrastructure required to develop advanced cell therapies through automation and streamlined logistics. The new Center of Excellence provides a strong foundation to realize this vision.”
